Collaborating with GMT, Take2 Prophecy™ is Currently Available Across the Philippines
Take2 Health (“Take2”) and Global Medical Technologies (“GMT”) collaborate on the distribution of the Take2 Prophecy™ Test for Nasopharyngeal Cancer (“NPC”) in the Philippines.
GMT is a local medical distribution group that aids doctors in finding the root cause of diseases through scientific knowledge by introducing advanced diagnostic services from overseas to Filipinos. The services that GMT provides target a variety of indications, such as oncology, nutrition, internal medicine, and dermatology.
With GMT’s extensive local healthcare network, the partnership is expected to signify an in-depth exploration of the local market, and allow the Take2 Prophecy™ Test for NPC to become accessible to most major cities in this region with high NPC incidence rate.
More Latest News
Nasopharyngeal Cancer Screening Results May “Predict” Development of Related Cancer and Improve Early Diagnosis, CUHK Study Finds
A recent study conducted by The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) has shown that individuals with detectable plasma Epstein–Barr virus (EBV) DNA but without an immediately identifiable nasopharyngeal cancer (NPC) after further investigation with nasal endoscopic examination and magnetic resonance imaging (MRI), have a higher risk of developing NPC in 3 to 5 years, up to 17 times higher than those tested “negative” in the test. The non-invasive liquid biopsy techniques not only could be used for early cancer detection but may also indicate the risk for future cancer development.
Promoting NPC Awareness across the City
Joining Hands with Bowtie to Sponsor the Take2 Prophecy™ Test for Nasopharyngeal Cancer to the High-risk Group
Awarded as The Company with the Most Investment Potential & The Top Breakthrough Innovation
Take2 Health are privileged to have participated in the first ZAODX World Conference on Early Detection of Cancer, and are very honoured to be awarded as The Company with the Most Investment Potential (金篩獎‧最具投資價值潛力企業) as well as The Top Breakthrough Innovation (金篩獎‧突破性創新獎)
